Bristol-Myers Squibb Company
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B |
| Cost of Revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B |
| Gross Profit | $9.25B | $8.07B | $8.41B | $8.79B | $8.90B | $8.17B | $7.53B | $8.94B |
| Gross Margin | 71.3% | 70.2% | 67.2% | 71.9% | 72.5% | 72.9% | 61.0% | 75.1% |
| Operating Expenses | ||||||||
| Research & Development | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B | $2.37B |
| SG&A Expense | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B |
| Operating Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175.0M | $1.68B |
| Operating Margin | 31.5% | 28.2% | 11.8% | 25.5% | 14.5% | 26.5% | 1.4% | 14.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175.0M | $1.68B |
| Income Tax Expense | $770.0M | $561.0M | $384.0M | $919.0M | $460.0M | $509.0M | $99.0M | $461.0M |
| Net Income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72.0M | $1.21B |
| Net Margin | 25.6% | 23.3% | 8.7% | 18.0% | 10.7% | 21.9% | 0.6% | 10.2% |
| EPS (Basic) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.21 | $0.05 | $0.60 |
| EPS (Diluted) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.20 | $0.05 | $0.60 |
| Shares Outstanding (Basic) | 2.04B | 2.04B | 2.03B | 2.04B | 2.04B | 2.03B | 2.03B | 2.03B |
| Shares Outstanding (Diluted) | 2.05B | 2.05B | 2.04B | 2.04B | 2.04B | 2.04B | 2.03B | 2.03B |
| Dividends Per Share | $0.63 | $0.63 | $0.63 | $0.62 | $0.62 | $0.62 | $0.62 | $0.60 |